Literature DB >> 8693871

In vitro activity of amoxycillin/clavulanate and ticarcillin/clavulanate compared with that of other antibiotics against anaerobic bacteria: comparison with the results of the 1987 survey.

D Pierard1, A De Meyer, P Rosseel, M Van Cauwenbergh, M J Struelens, M Delmee, H Goossens, G Claeys, Y Glupczynski, L Verbist, P Melin, S Lauwers.   

Abstract

The activity of amoxycillin/clavulanate (Augmentin) and ticarcillin/ clavulanate (Timentin) was tested against 351 strict anaerobic clinical isolates collected from September 1993 to April 1994 in eight Belgian university hospitals and compared with that of 8 other antibiotics using the NCCLS reference agar dilution procedure. Production of beta-lactamase was detected by the nitrocefin test in 48% of the isolates. At NCCLS-recommended breakpoints, more than 90% of isolates were susceptible to amoxycillin/clavulanate, ticarcillin/clavulanate, piperacillin/tazobactam, imipenem, chloramphenicol and metronidazole but only 77%, 72% and 48% to cefoxitin, clindamycin and penicillin, respectively. In comparison with the results of a similar survey conducted in 1987 no major changes in susceptibility were observed except for the susceptibility to clindamycin that declined from 83% to 72% overall, and from 83% to 66% in the B. fragilis group. Furthermore one isolate of Clostridium clostridioforme was found produce beta-lactamase and few B. fragilis group isolates showed reduced susceptibility to metronidazole.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8693871     DOI: 10.1080/17843286.1996.11718489

Source DB:  PubMed          Journal:  Acta Clin Belg        ISSN: 1784-3286            Impact factor:   1.264


  2 in total

Review 1.  Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections.

Authors:  C M Perry; A Markham
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

2.  Fourth Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria.

Authors:  Ingrid Wybo; Dorien Van den Bossche; Oriane Soetens; Evilien Vekens; Kristof Vandoorslaer; Geert Claeys; Youri Glupczynski; Margareta Ieven; Pierrette Melin; Claire Nonhoff; Hector Rodriguez-Villalobos; Jan Verhaegen; Denis Piérard
Journal:  J Antimicrob Chemother       Date:  2013-09-05       Impact factor: 5.790

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.